VOR Live signals | Maximize Profits with Getagraph.com

Live Chart Being Loaded With Signals

Commentary (24 Apr 2024 @ 16:00):

Stats
Today's Volume	286 825
Average Volume	323 037
Market Cap	118.70M
EPS	$0 ( 2024-03-28 )
Next earnings date	( $-0.370 ) 2024-05-09
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.990
ATR14	$0.00400 (0.23%)

Insider Trading

Date	Person	Action	Amount	type
2024-03-01	Jorgensen Nathan D.	Sell	6 310	Common Stock
2024-03-01	Chakraborty Tirtha	Sell	5 576	Common Stock
2024-03-01	Ang Robert	Sell	12 657	Common Stock
2024-02-06	Attar Eyal C.	Sell	1 180	Common Stock
2024-02-06	Ang Robert	Sell	2 788	Common Stock

INSIDER POWER
97.60
Last 99 transactions
Buy: 33 478 720 \| Sell: 91 989 993

Volume Correlation

Long: -0.17 (neutral)

Short: 0.00 (neutral)

Signal:(56.6) Neutral

Vor Biopharma Inc. Correlation

10 Most Positive Correlations
BNIXU	0.936
NUTX	0.88
WEN	0.85
GLMD	0.847
SBEAU	0.833
ATIF	0.816
BGNE	0.806
FRAF	0.801
KTRA	0.801

10 Most Negative Correlations
WTER	-0.873
HOOK	-0.827
SLDP	-0.82
GSM	-0.816
MTEK	-0.815
PMD	-0.815
GRAY	-0.802

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Vor Biopharma Inc. Correlation - Currency/Commodity

-0.43
( neutral )

-0.71
( moderate negative )

0.00
( neutral )

0.35
( neutral )

0.05
( neutral )

Vor Biopharma Inc. Financials

Annual	2023
Revenue:	$0
Gross Profit:	$-3.49M (0.00 %)
EPS:	$-1.750

Q4	2023
Revenue:	$0
Gross Profit:	$-892 000 (0.00 %)
EPS:	$-0.390

Q3	2023
Revenue:	$0
Gross Profit:	$-2.09M (0.00 %)
EPS:	$-0.490

Q2	2023
Revenue:	$0
Gross Profit:	$-1.23M (0.00 %)
EPS:	$-0.450

Financial Reports:

No articles found.

Vor Biopharma Inc.

Vor Biopharma, Inc., a clinical-stage company, develops engineered hematopoietic stem cell (eHSC) therapies for cancer patients. It is developing VOR33, an eHSC product candidate that is in phase 1/2 to treat acute myeloid leukemia (AML) and other hematological malignancies. The company's VOR33 eHSCs lacks CD33, a protein that is expressed by AML blood cancer cells. The company's eHSCs targeted therapies, such as CAR-Ts, bispecific antibodies, and antibody-drug conjugates provide treatment for blood cancers. Vor Biopharma, Inc. has a collaboration agreement with Akron BioProducts to develop and manufacture cGMP nucleases. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.